Penumbra Inc·4

Feb 18, 8:03 PM ET

Wilder Thomas 4

4 · Penumbra Inc · Filed Feb 18, 2026

Research Summary

AI-generated summary of this filing

Updated

Penumbra (PEN) Director Wilder Thomas Receives 589-Share Award

What Happened

  • Wilder Thomas, a director of Penumbra, was granted 589 restricted stock units (RSUs) on February 13, 2026. The RSUs were awarded at $0.00 per share (total value on grant = $0) as a compensation award (transaction code A). This is an issuance of equity-based compensation, not an open-market purchase or sale.

Key Details

  • Transaction date: 2026-02-13; Form 4 filed 2026-02-18 (timely filing given the Feb 16 federal holiday).
  • Grant: 589 RSUs at $0.00 (award/acquisition).
  • Vesting: 1/4 vests on each of Mar 31, Jun 30, Sep 30, and Dec 31, 2026, subject to continued service; any unvested RSUs will fully vest upon the Closing of the merger with Boston Scientific (per the Jan 14, 2026 merger agreement).
  • A portion of the shares is subject to vesting; the filing notes the shares are held by the Thomas and Catharine Wilder Family Trust (dated Mar 31, 2006).
  • Shares owned after the transaction are not specified in the filing.

Context

  • RSUs are a common form of executive/director compensation and represent a promise to deliver shares in the future if vesting conditions are met; they do not necessarily reflect a personal buy or sell decision.
  • The grant includes acceleration language tied to the announced merger with Boston Scientific, meaning unvested awards could vest sooner if the deal closes.

Insider Transaction Report

Form 4
Period: 2026-02-13
Transactions
  • Award

    Common Stock

    [F1][F2]
    2026-02-13+589589 total
Holdings
  • Common Stock

    [F3]
    (indirect: By Trust)
    4,506
Footnotes (3)
  • [F1]Restricted stock units (RSUs) vest as to 1/4 on each of March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026, subject to Mr. Wilder's continued service as director through such dates. Notwithstanding the foregoing, if the Closing (as defined in that certain Agreement and Plan of Merger, dated as of January 14, 2026, among the Issuer, Boston Scientific Corporation, a Delaware corporation, and Pinehurst Merger Sub, Inc., a Delaware corporation) occurs, any of the RSUs that remain unvested will fully vest on the Closing, subject to Mr. Wilder's continued service as director through such date.
  • [F2]A portion of these shares is subject to vesting.
  • [F3]Shares are held by the Thomas and Catharine Wilder Family Trust dated March 31, 2006.
Signature
/s/ Johanna Roberts, as attorney-in-fact for Thomas C. Wilder|2026-02-18

Documents

1 file
  • 4
    wk-form4_1771463016.xmlPrimary

    FORM 4